natgillin/translations-raw huggingface dataset:
increased LDH,
povećana razina
Increased left ventricular output and increased stroke volume
povećan minutni volumen i povećan udarni volumen
increased level of alkaline phosphatase in the blood ,
povećanje razine alkalne fosfataze u krvi,
increased level of bilirubin, a substance produced by the liver
povišena razina bilirubina, tvari koju proizvodi jetra
Increased level of C-reactive protein, which can be seen in results of blood tests
Porast razine C-reaktivnog proteina, koji se može otkriti krvnim pretragama.
increased level of calcium in the blood,
povećanje razine kalcija u krvi,
increased level of calcium in the urine, nausea.
povećanje razine kalcija u urinu, mučnina
Increased level of creatinine in the blood
povišena razina kreatinina u krvi
increased level of potassium in your blood and
povišena razina kalija u krvi i
increased level of the serum protein known as lipase
povišena razina serumskog proteina zvanog lipaza
increased level of uric acid in the blood,
povećanje razine urične kiseline u krvi,
Increased levels of activated NovoThirteen may increase the risk of thrombosis.
Povišene razine aktiviranog lijeka NovoThirteen mogu povećati rizik od tromboza.
increased levels of bilirubin in the blood (hyperbilirubinaemia)
povećanje razine bilirubina u krvi (hiperbilirubinemija)
Increased levels of calcium in your blood.
povišena razina kalcija u krvi.
increased levels of cholesterol and/or pancreatic amylase (a digestive enzyme) in the blood increased levels of liver enzymes in the blood
povišene razine kolesterola i/ili pankreasne amilaze (probavnog enzima) u krvi povišene razine enzima jetre u krvi
Increased levels of creatine kinase in the blood that may result in muscle pain and weakness
povišene razine kreatin kinaze u krvi, što može rezultirati mišićnim bolovima i slabošću
Increased levels of glucose in your blood.
povišena razina glukoze u krvi.
increased levels of insulin, a hormone regulating blood sugar levels
povišene razine inzulina, hormona koji regulira razine šećera u krvi
Increased levels of pro-inflammatory cytokines (e.g.
Pokazalo se da povišene razine proupalnih citokina (npr.
Increased levels of small blood cells (called platelets), which are normally involved in the formation of a blood clot may occur.
Može se pojaviti povećana razina malih krvnih stanica (koje se nazivaju krvne pločice) koje su normalno uključene u stvaranje krvnog ugruška.
increased levels of the enzyme (creatine kinase) in your blood
povećane razine enzima (kreatin kinaze) u krvi
Increased levels of the enzyme alkaline phosphatase in the blood (an indicator of organ malfunction or injury, particularly liver, pancreas, bone, thyroid gland, or gall bladder).
povećane razine enzima alkalne fosfataze u krvi (pokazatelj disfunkcije ili oštećenja organa, naročito jetre, gušterače, kosti, štitnjače ili žučnog mjehura).
increased levels of the hormone prolactin in your blood
ako imate povišenu razinu hormona prolaktin u krvi
Increased levels of the liver enzymes (aspartate aminotransferase and alanine aminotransferase) in blood tests.
Povišene vrijednosti jetrenih enzima (aspartat aminotransferaze i alanin aminotransferaze) u krvnim pretragama
increased levels of the serum proteins lipase or amylase.
povišene razine proteina lipaza ili amilaza u serumu.
increased levels of triglycerides (fats) in your blood
povišene razine triglicerida (masnoća) u krvi
increased levels of white blood cell count, decreased levels of certain white blood cells (lymphopenia)
povišene razine broja bijelih krvnih stanica, smanjene razine određenih bijelih krvnih stanica (limfopenija)
increased levels of “ketone bodies” in your urine or blood
povišene razine “ketonskih tijela” u mokraći ili krvi
increased levels of “ketone bodies” in your urine or blood
povišene razine „ketonskih tijela“ u mokraći ili krvi
increased levels of “ketone bodies” in your urine or blood
povišene razine „ketonskih tijela” u mokraći ili krvi
increased libido
pojačan libido
Increased lipase* Increased amylase*
Povišena lipaza* Povišena amilaza
Increased lipase, increased amylase
povišene razine lipaze, povišene razine amilaze
increased lipids in the blood elevated liver enzymes
povišena razina lipida u krvi povišena razina jetrenih enzima
increased lipids in the blood; elevated liver enzymes.
povišena razina lipida u krvi, povišena razina jetrenih enzima.
increased liver enzyme levels in the blood; abnormal kidney function test reaction related to the infusion of the medicine
povišene vrijednosti jetrenih enzima u krvi; odstupanja u nalazima testova funkcije bubrega reakcija povezana s infuzijom ovog lijeka
Increased liver enzyme values (alanine aminotransferase, aspartate aminotransferase, blood alkaline phosphatase) in the blood as seen from blood tests
Porast vrijednosti jetrenih enzima (alanin aminotransferaze, aspartat aminotransferaze, alkalne fosfataze) u krvi vidljiv iz krvnih pretraga.
Increased liver enzyme values (gamma-glutamyltransferase) in the blood as seen from blood tests
Porast vrijednosti jetrenih enzima (gama-glutamiltransferaze) u krvi kao što se vidi iz krvnih pretraga
increased liver enzymes
povećane vrijednosti jetrenih enzima
increased liver enzymes
povišene vrijednosti jetrenih enzima
increased liver enzymes
povišeni jetreni enzimi
increased liver enzymes (shown in blood tests)
povišene vrijednosti jetrenih enzima (vidljive u nalazima krvnih pretraga)
increased liver enzymes (shown in blood tests)
povišeni jetreni enzimi (što se vidi iz krvnih nalaza)
Increased liver enzymes and bilirubin levels, liver disorders, hepatitis
povećane razine jetrenih enzima i bilirubina, poremećaji jetre, upala jetre (hepatitis)
Increased liver enzymes in the blood have been seen in some people receiving ivacaftor.
Neki ljudi koji uzimaju ivakaftor mogu imati povišene jetrene enzime u krvi.
increased liver enzymes in the blood increased triglycerides (fatty acids) in the blood
povišene razine jetrenih enzima u krvi povišene razine triglicerida (masnih kiselina) u krvi
increased liver enzymes in the blood increased triglycerides (fatty acids) in the blood
povišene vrijednosti jetrenih enzima u krvi povišene vrijednosti triglicerida (masnih kiselina) u krvi
increased liver enzymes in the blood increased trigycerides (fatty acids) in the blood
povišene vrijednosti jetrenih enzima u krvi povišene vrijednosti triglicerida (masnih kiselina) u krvi
Increased liver function tests
povišene vrijednosti jetrenih proba
Increased liver function tests
povišene vrijednosti pretraga funkcije jetre
increased liver transaminases in your blood
povišene jetrene transaminaze u krvi
increased liver, renal and digestive enzymes
povećanje jetrenih, bubrežnih i enzima probavnog trakta
increased menstrual bleeding
pojačano menstrualno krvarenje
Increased menstrual flow,
pojačana mjesečnica
Increased methadone dose may
ketokonazola dovela je do povećane
Increased methadone dose may be necessary when concomitantly administered with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer due to induction of glucuronidation.
Metadon1 5, jednokratna doza 500 svakih 12h, ↓ 36% ↓ 38% Zbog indukcije glukuronidacije, može biti potrebno povećati dozu metadona kada se daje istodobno s ritonavirom doziranim kao antiretrovirusnim lijekom ili kao farmakokinetičkim pojačivačem.
Increased minimum inhibitory concentration (MIC) values have been found in some isolates of Histophilus somni and Actinobacillus pleuropneumoniae. .
Povišene vrijednosti minimalne inhibitorne koncentracije (MIK) pronađene su u nekim izolatima Histophilus somni i Actinobacillus pleuropneumoniae.
Increased monitoring (i.e. prior to initiation of therapy, every two weeks during the first three months of treatment, then monthly until 48 weeks, and then every eight to twelve weeks thereafter) is warranted when Aptivus and low dose ritonavir are administered to patients with elevated ASAT and ALAT levels, mild hepatic impairment, chronic hepatitis B or C, or other underlying liver disease.
U bolesnika s povišenim vrijednostima AST/ALT, blagim oštećenjem jetre, kroničnim hepatitisom B ili C, ili drugom bolešću jetre, praćenje jetrene funkcije mora biti pojačano (tj. prije početka liječenja, svaka dva tjedna tijekom prva tri mjeseca liječenja, zatim jednom do 48 tjedana, i nakon toga svakih osam do dvanaest tjedana).
Increased monitoring for
Traži se pojačan nadzor
Increased monitoring for rifabutin- associated adverse reactions including neutropenia and uveitis is recommended.
Preporučuje se pojačan nadzor zbog nuspojava povezanih s rifabutinom uključujući neutropeniju i uveitis.
Increased monitoring for rifabutin- associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to rifabutin.
Upozorava se na pojačano praćenje nuspojava povezanih s rifabutinom uključujući neutropeniju i uveitis zbog povećane izloženosti rifabutinu.
Increased monitoring for rifabutin-associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to desacetyl-rifabutin.
Potreban je strog nadzor nuspojava povezanih s rifabutinom, uključujući neutropeniju i uveitis zbog očekivanog povećanja izloženosti dezacetil-rifabutinu.
Increased monitoring for rifabutin-associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to desacetyl-rifabutin.
Potreban je stroži nadzor nuspojava povezanih s rifabutinom, uključujući i neutropeniju i uveitis zbog očekivanog povećanja izloženosti desacetil-rifabutinu.
Increased monitoring for rifabutin-associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to rifabutin.
povećanja neuromuskularne toksičnosti povezane s kolhicinom (uključujući rabdomiolizu),
Increased mortality and morbidity were seen at all doses (1 mg/kg/day) in lactating females in mouse pre- and postnatal development studies.
U ispitivanjima prenatalnog i postnatalnog razvoja na miševima, primijećeni su povećana smrtnost i pobol ženki u laktaciji kod primjene svih doza (1 mg/kg na dan).
increased mucous, phlegm
pojačana sluz, gusti iskašljaj
Increased muscle stiffness
pojačana ukočenost mišića
increased muscle stiffness and inability to stretch
povećana napetost mišića i nemogućnost istezanja
increased muscle tension
povećana napetost mišića
Increased muscle tension, difficulty with speech, difficulty with coordination, reduced sense of taste, altered sleep pattern
povećana napetost mišića, poteškoće s govorom, poteškoće s koordinacijom, smanjeni osjet okusa, promijenjen obrazac spavanja
increased muscle tone or tension (hypertonia)
povećani tonus ili napetost mišića (hipertonija)
Increased need for diabetes medicine, salt imbalance, potassium loss due to low carbon dioxide levels (a condition called metabolic alkalosis);
Povećana potreba za lijekovima protiv dijabetesa, neravnoteža soli, gubitak kalija zbog malih razina ugljikovog dioksida (stanja nazvanog metabolička alkaloza);
increased need to pass water
pojačan nagon na mokrenje
increased need to urinate at night
pojačana potreba za mokrenjem noću
increased need to urinate, or to urinate more frequently
povećana potreba za mokrenjem, ili češće mokrenje
increased need to urinate, to urinate at night, or to urinate more frequently thirst (requiring excessive drinking of water)
povećana potreba za mokrenjem, mokrenjem noću, učestalijim mokrenjem žeđ (koja zahtijeva povećani unos vode)
Increased number of certain white blood cells (eosinophils).
povećan broj određenih bijelih krvnih stanica (eozinofila)
increased number of red blood cells
povećan broj crvenih krvnih stanica
increased number of times of passing urine
povećan broj mokrenja
increased number of white blood cells (leucocytosis), itching (pruritus), skin inflammation (exfoliative dermatitis), rash.
povećan broj bijelih krvnih stanica (leukocitoza), svrbež (pruritus), upala kože (eksfolijativni dermatitis), osip.
increased number of white blood cells called monocytes
povećani broj bijelih krvnih stanica koje se nazivaju monociti
increased or abnormal liver function test results
povišeni ili poremećeni testovi funkcije jetre
Increased or decreased amount of calcium or potassium
povećana ili smanjena količina kalcija ili kalija
increased or decreased appetite
pojačan ili oslabljen apetit
increased or decreased appetite, weight gain
pojačan ili oslabljen apetit, povećanje tjelesne težine
Increased or decreased urine production (due to kidney damage), painful passing of urine or blood/proteins in the urine, fluid retention
pojačana ili smanjena proizvodnja mokraće (zbog oštećenja bubrega), bolno mokrenje ili krv/bjelančevine u mokraći, zadržavanje tekućine
Increased or high blood pressure
povišen ili visok krvni tlak
increased or irregular heart rate
ubrzan ili nepravilan rad srca
increased or reduced sense of touch or sensation, abnormal sensation such as prickling, tingling and itchiness
povećani ili smanjeni osjeti ili samo osjet dodira, neuobičajeni osjeti poput bockanja, trnaca i svrbeža
increased painful or burning urination,
učestalo bolno mokrenje ili mokrenje uz osjećaj pečenja,
increased pancreatic amylase
povišena pankreasna amilaza
increased pancreatic amylase2, vomiting1, 2, 3, diarrhoea1, 3, nausea1, 2, 3
povišena pankreasna amilaza2, povraćanje1, 2, 3, proljev1, 3, mučnina1, 2, 3
Increased plasma concentrations of amiodarone, bepridil, dronedarone, encainide, flecanide, propafenone, quinidine.
Povećane koncentracije amiodarona, bepridila, dronedarona, enkainida, flekanida, propafenona i kinidina u plazmi.
Increased plasma concentrations of amiodarone.
Povišena koncentracija amiodarona u plazmi.
Increased plasma concentrations of duloxetine occur in patients with severe renal impairment on haemodialysis (creatinine clearance <30 ml/min).
U bolesnica s teškim oštećenjem bubrežne funkcije (klirens kreatinina < 30 ml/min) koje su na hemodijalizi koncentracije duloksetina u plazmi su povećane.
Increased plasma concentrations of duloxetine occur in patients with severe renal impairment on haemodialysis (creatinine clearance <30 ml/min).
U bolesnika s teškim oštećenjem bubrežne funkcije (klirens kreatinina < 30 ml/min) koji su na hemodijalizi, koncentracije duloksetina u plazmi su povećane.
Increased plasma concentrations of ergot derivatives leading to acute ergot toxicity, including vasospasm and ischaemia.
Povišena koncentracija derivata ergota u plazmi koja vodi do akutne ergotne toksičnosti, uključujući vazospazam i ishemiju.
Increased plasma concentrations of medicinal products that are metabolised by CYP3A (including atazanavir and darunavir) are observed on co-administration with cobicistat.
Povećane plazmatske koncentracije lijekova koji se metaboliziraju putem CYP3A (uključujući atazanavir i darunavir) su zapažene kod istovremene primjene s kobicistatom.
Increased plasma concentrations of medicinal products that are metabolised by CYP3A (including atazanavir and darunavir) are observed on co-administration with cobicistat.
Povećane plazmatske koncentracije lijekova koji se metaboliziraju putem CYP3A (uključujući atazanavir i darunavir) zapažene su kod istovremene primjene s kobicistatom.
Increased plasma concentrations of oral midazolam and triazolam.
Povišena koncentracija oralnog midazolama i triazolama u plazmi.
Increased plasma concentrations of quetiapine may lead to coma (see section 4.3).
Povećane koncentracije kvetiapina u plazmi mogu dovesti do kome (vidjeti dio 4.3).
Increased plasma concentrations of simeprevir are expected.
Očekuju se povišene koncentracije simeprevira u plazmi.
Increased plasma concentrations of tenofovir resulting from co-administration of tenofovir disoproxil fumarate, ledipasvir/sofosbuvir and atazanavir/ritonavir may increase adverse reactions related to tenofovir disoproxil fumarate, including renal disorders.
Povećane koncentracije tenofovira u plazmi uslijed istovremene primjene tenofovirdizoproksilfumarata, ledipasvira/sofosbuvira i atazanavira/ritonavira mogu pojačati nuspojave vezane uz tenofovirdizoproksilfumarat, uključujući poremećaje bubrega.
Increased post-implantation loss was observed in both the fertility study, which involved treatment of both males and females, and the embryotoxicity study, which involved treatment of females.
Povećani postimplantacijski gubici opaženi su u ispitivanjima fertilnosti u oba spola, kao i u embriotoksičnom ispitivanjima, u kojima su bile liječene ženke.
Increased pressure in the brain (intracranial hypertension)
Povećani tlak u mozgu (intrakranijska hipertenzija)
increased pressure in the eye (glaucoma)
povišen očni tlak (glaukom)
Increased pressure in the eye (glaucoma), lacrimation increased
povećan tlak u oku (glaukom), pojačano suzenje
Increased pressure in the eye (glaucoma).
povišen očni tlak (glaukom).
increased pressure in the eye (glaucoma);
povišen očni tlak (glaukom)
Increased pressure in the eye including glaucoma, choroid and retinal disorders (chorioretinopathy);
Povišeni tlak u oku uključujući glaukom, poremećaji koroida i mrežnice (korioretinopatija);
Increased pressure in the eye, clouding of the lens (cataract), bleeding on the surface of the eye*
Porast tlaka u oku, zamućenje leće (mrena), krvarenje na površini oka
increased pressure inside the eye
povišen tlak u oku,
increased pressure within muscles of the legs or arms after a bleeding, which leads to pain, swelling, altered sensation, numbness or paralysis (compartment syndrome after a bleeding) kidney failure after a severe bleeding
povećan tlak u mišićima nogu ili ruku nakon krvarenja, što uzrokuje bol, oticanje, promjenu osjeta, utrnulost ili paralizu (kompartment sindrom nakon krvarenja) zatajenje bubrega nakon teškog krvarenja
increased pressure within muscles of the legs or arms after a bleeding, which leads to pain, swelling, altered sensation, numbness or paralysis (compartment syndrome after a bleeding) kidney failure after a severe bleeding
povećan tlak u mišićima nogu ili ruku nakon krvarenja, što uzrokuje boli, oticanje, promjenu osjeta, utrnulost ili paralizu (kompartment sindrom nakon krvarenja) zatajenje bubrega nakon teškog krvarenja
increased production of saliva
povećano stvaranje sline
increased production of saliva;
zatvor, pojačano stvaranje sline,
Increased production of tears, conjunctivitis (redness and soreness of the surface of the eye), nosebleed
povećano stvaranje suza, konjunktivitis (crvenilo i osjetljivost površine oka), krvarenje iz nosa
Increased protein (c-reactive protein) in blood indicating inflammation
Povišeni protein (C-reaktivni protein) u krvi što ukazuje na upalu
Increased protein levels in urine
Povećane razine proteina u urinu
Increased prothrombin time (PT), increased partial thromboplastin time (PTT), and hypofibrinogenemia can occur in patients receiving Oncaspar.
Produljeno protrombinsko vrijeme (PT), produljeno parcijalno tromboplastinsko vrijeme (PTT) i hipofibrinogenemija mogu se pojaviti u bolesnika koji primaju Oncaspar.
Increased pulse
Ubrzani puls
Increased rates of severe neutropenia, febrile neutropenia, or infection with or without severe neutropenia (including some fatalities) have been observed mainly in patients treated with platinum- or taxane-based therapies in the treatment of NSCLC and mBC.
Povećane stope teške neutropenije, febrilne neutropenije te infekcije praćene teškom neutropenijom ili bez nje (s nekoliko smrtnih ishoda) opažene su većinom u bolesnika koji su primali kemoterapiju na bazi platinskog spoja ili taksana u liječenju karcinoma pluća nemalih stanica i metastatskog karcinoma dojke.
Increased reporting rates of convulsions (with or without fever) and hypotonic hyporesponsive episode (HHE) were observed with concomitant administration of Infanrix hexa and Prevenar 13 (see section 4.8).
Opažena je povećana stopa prijava konvulzija (s vrućicom ili bez nje) te hipotonično hiporesponzivne epizode (HHE) kod istodobne primjene cjepiva Infanrix hexa i Prevenar 13 (vidjeti dio 4.8.)
Increased reporting rates of convulsions (with or without fever) and hypotonic hyporesponsive episode (HHE) were observed with concomitant administration of Prevenar 13 and Infanrix hexa (see section 4.8).
Uočena je povećana stopa prijavljivanja konvulzija (s ili bez vrućice) i hipotono- hiporesponzivne epizode (HHE) s istovremenom primjenom Prevenara 13 i Infanrix hexa (vidjeti dio 4.8).
Increased representation of memory T- and B-lymphocytes
Povećanje udjela memorijskih T i B limfocita
Increased representation of regulatory T cell subsets
Povećanje udjela podskupina regulatornih T stanica
Increased requirements for use of reliever medication (short-acting bronchodilators), or decreased response to reliever medication indicate deterioration of asthma control and patients should be reviewed by a physician.
Povećana potreba za primjenom lijeka za brzo ublažavanje simptoma (kratkodjelujućih bronhodilatatora) ili smanjeni odgovor na lijek za brzo ublažavanje simptoma ukazuju na slabljenje kontrole astme i bolesnike treba pregledati liječnik.
increased risk of adverse
nuspojava.
Increased risk of bleeding.
Povećan rizik od krvarenja
Increased risk of bleeding.
Povećan rizik od krvarenja.
Increased risk of blood clots in the eyes (retinal vein thrombosis)
povećan rizik od krvnih ugrušaka u očima (tromboza vene retine)
Increased risk of blood clots in the eyes (retinal vein thrombosis).
povećan rizik od krvnih ugrušaka u očima (tromboza vene retine).
Increased risk of blood clots in the legs (deep vein thrombosis)
povećan rizik od krvnih ugrušaka u nogama (duboka venska tromboza)
Increased risk of blood clots in the legs (deep vein thrombosis).
povećan rizik od krvnih ugrušaka u nogama (duboka venska tromboza).
Increased risk of blood clots in the lungs (pulmonary embolism)
povećan rizik od krvnih ugrušaka u plućima (plućna embolija)
Increased risk of blood clots in the lungs (pulmonary embolism).
povećan rizik od krvnih ugrušaka u plućima (plućna embolija).
Increased risk of cardiac arrhythmias and torsades de pointes/wave burst arrhythmia in particular.
Povećanje rizika od srčanih aritmija, a osobito od ventrikularne aritmije tipa torsades de pointes.
increased risk of death when administered to achieve a haemoglobin concentration level of 12 g/dl (7.5 mmol/l) in patients with active malignant disease receiving neither chemotherapy nor radiation therapy.
povećan rizik od smrti, kada se primjenjivao s ciljem postizanja vrijednosti koncentracije hemoglobina od 12 g/dl (7,5 mmol/l) u bolesnika s aktivnom malignom bolešću koji nisu primali ni kemoterapiju niti terapiju zračenjem.
increased risk of death when administered to target a haemoglobin of 12 g/dl (7.5 mmol/l) in patients with active malignant disease receiving neither chemotherapy nor radiation therapy.
povećani rizik od smrti kod primjene radi ciljne koncentracije hemoglobina od 12 g/dl (7,5 mmol/l) kod bolesnika s aktivnom malignom bolešću koji ne primaju kemoterapiju niti radioterapiju.
Increased risk of dose-dependent adverse reactions such as rhabdomyolysis (decreased hepatic metabolism of cholesterol-lowering agent).
Povećanje rizika od nuspojava ovisnih o dozi kao što je rabdomioliza (smanjen hepatički metabolizam tvari koja snižava razinu kolesterola).
increased risk of getting a oestrogen-sensitive cancer (such as having a mother, sister or grandmother who has had breast cancer)
povećani rizik od dobivanja raka osjetljivog na estrogen (primjerice ako su vam majka, sestra ili baka imale rak dojke)
increased risk of grade 3-4 hypertension (including hypertension and one case of essential hypertension) has been observed in patients receiving the ZALTRAP/FOLFIRI regimen.
U bolesnika liječenih protokolom ZALTRAP/FOLFIRI primijećen je povećan rizik od hipertenzije stupnja 3-4 (uključujući hipertenziju i jedan slučaj esencijalne hipertenzije).
Increased risk of haemorrhage
Povećan rizik za nastanak krvarenja
Increased risk of side-effects (respiratory depression, sedation) due to higher plasma concentrations because of CYP3A4 inhibition by Kaletra
Povećan rizik od nuspojava (depresija disanja, sedacija) uslijed viših koncentracija u plazmi, nastalih zbog inhibicije CYP3A4 lijekom Kaletra
increased saliva (drooling)
pojačano lučenje sline (slinjenje)